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RESEARCH ARTICLE Open Access
Comparing the case mix and survival of
women receiving breast cancer care from
one private provider with other London
women with breast cancer: pilot data
exchange and analyses
Elizabeth A. Davies1,2,4*, Victoria H. Coupland1, Steve Dixon3, Kefah Mokbel3 and Ruth H. Jack1
Abstract
Background: Data from providers of private cancer care are not yet formally included in English cancer registration
data. This study aimed to test the exchange of breast cancer data from one Hospital Corporation of America
International (HCAI) hospital in London with the cancer registration system and assess the suitability of these data
for comparative analyses of case mix and adjusted survival.
Methods: Data on 199 London women receiving ‘only HCAI care’, 278 women receiving ‘some HCAI care’ (HCAI
and other services), and 31,234 other London women diagnosed between 2005 and 2011 could be identified and
compared. Overall survival was estimated using the Kaplan-Meier method, and Cox regression was used to adjust
for age, socioeconomic deprivation, year of diagnosis, stage of disease and recorded treatment.
Results: Women receiving ‘only HCAI care’ were younger, lived in areas of higher affluence (47.8 % vs 27.6 %) and
appeared less likely to be recorded as having screen-detected (2.5 % vs 25.0 %) disease than other London women.
Women receiving ‘some HCAI care’ were more similar to ‘HCAI only’ women. Although HCAI stage of disease data
completeness improved during the study period, this was less complete overall than cancer registration data and
limited the comparative survival analyses. An apparent survival advantage for ‘HCAI only’ women compared with
other London women (hazard ratio 0.48, 95 % confidence interval (CI): 0.32-0.74) was attenuated and no longer
statistically significant after adjustment (0.79, 95 % CI: 0.51-1.21). Women receiving ‘some HCAI care’ appeared to
have higher survival (hazard ratio 0.24, 95 % CI 0.14-0.41) which was attenuated to 0.48 (95 % CI: 0.28-0.80) in the
fully adjusted model.
Conclusions: Exchange of data between the private cancer sector and the English cancer registration service can
identify patients who receive all or some private care. The better survival of women receiving only or some HCAI
breast cancer care appears to be at least partly explained by demographic, disease, and treatment factors. However,
larger studies using similarly quality assured datasets and more complete staging data from the private sector are
needed to produce definitive comparative results.
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Background
Successive English health policies including the 2012
NHS Health and Social Care Act [1] have encouraged
some private sector health care organisations to become
interested in bidding for contracts to provide National
Health Service (NHS) care. The proportion of English
NHS spending delivered via non-NHS providers in-
creased from 2.8 % over 2006 to 2007 to 5.9 % over
2013 to 2014 [2] while people holding some form of pri-
vate health insurance declined from 12.5 % in 2006 to
10.9 % in 2012 [3]. However data on clinical outcomes
for patients in the private sector remain sparse com-
pared to those available for NHS care.
In the absence of comparative data the terms of en-
gagement by which the private sector bid in competition
with the NHS to provide a service remain controversial.
Opponents have argued that private providers could opt
to treat less complex cases and do not pay the full costs
of medical complications or staff training, while some
private providers have argued they are offered too few
opportunities to bid and that payment does not reflect
the full cost of service provision [4]. Other issues being
debated include the potential benefits of private sector
investment, innovation, and competition for the NHS,
versus the risks posed by an uncertain health care mar-
ket, new bureaucracy costs, a two tier system of services,
and lack of strategic planning [5].
A key question in the debate about the provision of
private services for the NHS must be whether the pa-
tients currently treated by private providers differ signifi-
cantly in case mix, or have better outcomes than those
treated by the NHS after these are taken into account.
There are few published studies on this topic although
analyses of data on NHS patients referred to independ-
ent treatment centres for routine surgical procedures
suggest they are healthier, more affluent, and report bet-
ter outcomes and fewer complications than similar pa-
tients treated at NHS hospitals [6–8]. While some
private providers are now making information about pa-
tient experience, hospital acquired infection, and out-
comes such as cardiac surgery survival available [9],
detailed comparative information on the case mix and
outcomes of patients treated for cancer is not yet avail-
able. This is because the systems for recording informa-
tion on patients cared for in the private sector are less
well-developed, have not been the focus of successive
NHS policies for collection and quality assurance and
private providers do not have access to the routinely
available follow-up and death information collected for
NHS patients. Private providers have also sometimes
been excluded from national cancer audits despite a will-
ingness to share their data and report outcomes [10].
The Private Healthcare Information Network (PHIN) is
now developing with the aims of collecting much more
information for patients and of providing comparative
information on hospitals and consultants by 2017 [11].
Given the large numbers of people who can expect to
develop cancer during their lifetime, the lack of informa-
tion about outcomes for those who hold private insur-
ance or choose to pay for private cancer care represents
a gap in knowledge for English cancer policy. Historic-
ally data on some English patients receiving cancer care
from private providers have been collected and held by
the eight former regional cancer registries because pri-
vate patients often receive pathology services or some
part of their treatment in NHS hospitals. Registries have
developed increasingly formal arrangements for collect-
ing cancer data directly from private providers, but
coverage has tended to be patchy. It has not therefore
been possible to be sure that all privately diagnosed and
treated patients have been included in population-based
cancer registers. Information about these groups would
be of significant interest in understanding existing na-
tional analyses, extending analyses of cancer inequalities
and in making equitable policy decisions. For example,
it is established that breast cancer patients living in af-
fluent areas are more likely to have had their cancer di-
agnosed at an earlier stage of disease and to have a
better survival [12–14]. The exclusion of patients
treated privately from national and local analyses of
cancer survival could, therefore, lead to an underesti-
mate of current survival as well as in inequalities in
survival between different socioeconomic groups. Data
on London women whose breast cancer was detected
by screening between 1999 and 2006 also suggested an
under-representation of those in highest socioeconomic
group whose cancers might have been detected by pri-
vate screening services [15, 16].
To our knowledge no published UK studies have ana-
lysed data on cancer patients treated by private providers
or compared their outcomes to those treated by NHS or
other private services. We believe that access to data
from private providers of a similar quality to those avail-
able for NHS would enable new analyses with the poten-
tial to benefit all patients. The aims of this pilot study
were 1) to test a method of data extraction and exchange
between one private provider - the Hospital Corporation
of America International (HCAI) - and the National
Cancer Registration Service (NCRS) in London and 2) to
examine the feasibility of comparing the case mix and
adjusted survival of women resident in London and
cared for by one HCAI provider with other London
women identified from cancer registration data and di-
agnosed and treated between 2005 and 2011. Our
intention in this study was to move towards the
provision of better national data from one private pro-
vider in order to build better evidence in this area rather
than to influence NHS policies for private cancer care.
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Methods
Data collection and processing
During the study period 2005 to 2011 cancer registration
for the area of South East England including London,
Kent, Surrey and Sussex was carried out by the former
Thames Cancer Registry (TCR) at King’s College London.
TCR received information about new cases of cancer
largely from National Health Service (NHS) hospitals in
the area and information on the deaths of residents from
the Office for National Statistics via the NHS Central
Register. Trained cancer registration officers extracted fur-
ther demographic and tumour details, and information on
whether patients had surgical, radiotherapy, chemotherapy
and hormonal treatment within six months of their diag-
nosis recorded in their medical records. Data were quality
assured as they were added to a central database and du-
plicate cases eliminated. Inpatient NHS Hospital Episode
Statistics (HES) data including self-assigned ethnicity data
were obtained from the NHS Information Centre each
year and linked to the registration data.
During the study period TCR received some informa-
tion on diagnoses or treatment within private health
care providers, often where pathological diagnoses were
undertaken for these providers by NHS hospitals, or
where patients went on to receive NHS care. One expe-
rienced cancer registration officer had also liaised with
private providers in London to collect additional data
on new diagnoses. This study aimed to complete data
collection for the cohort of patients seen at The
Princess Grace hospital, an HCAI provider in central
London, to a comparable standard for cases already
within the registry dataset. This hospital was chosen
because of the relatively large number of breast cancer
patients seen and the quality of the historical data
available. 46 % of patients receiving HCAI breast care
in London in 2010 were seen at the Princess Grace
Hospital.
The Princess Grace Hospital Breast Services, known as
the London Breast Institute, is one hospital within the
externally and internally quality assured and peer-
reviewed ISO 9001:2008 accredited HCAI cancer net-
work. Services provide breast screening annually from
the age of 40, breast diagnostic services including mam-
mography, ultrasound, breast MRI and PET CT. All
patients undergo triple assessment, including vacuum
assisted biopsy. Breast surgery and inpatient chemother-
apy are provided on site, and patients attend the Leaders
in Oncology Care clinic on Harley Street for day case
chemotherapy and The Harley Street Clinic for radio-
therapy (both within the HCAI cancer network). All
patients are discussed at weekly multi-disciplinary team
meetings and treatments are provided in accordance
with national and international guidelines including
NICE and the Association of Breast Surgery guidance.
The first phase of the study was to extract available
data from the central HCAI patient administration sys-
tems for the 1033 women recorded as seen at the study
hospital with a new diagnosis of breast cancer in the
years 2005 to 2011. These data were passed securely to
the Registry for initial matching against the registration
dataset in January 2013. Where HCAI records were in-
complete but the patient was known to the Registry,
data were updated using the registration dataset, includ-
ing whether the cancer was detected through NHS
screening, and whether the patient was known to have
died. This exercise revealed that 580 HCAI patients,
56 % of the complete cohort, had some data recorded
on the TCR dataset, but that the remainder were not
known to the Registry.
The second stage of new data collection was carried
out by the cancer registration officer who had worked
with private providers. This officer used the established
registry methods to extract and code data from HCAI
administrative, clinical, and results records. The coded
data was added on site by HCAI data staff to a database
designed for the study in consultation with the Registry.
HCAI staff also followed up all patients actively with cli-
nicians to determine if the patient was alive, or if not to
confirm the date of death. Where an overall disease
stage was missing, an experienced HCAI breast cancer
clinician (KM) reviewed all extracted data to assign a
Tumour, Node and Metastasis (TNM) stage.
In April 2013 the eight regional English cancer regis-
tries joined to become one single National Cancer Regis-
tration Service (NCRS) within Public Health England
(PHE), the new executive agency for public health. In
November 2013 the study dataset was passed securely
back to the London Office of the NCRS. The dataset
was traced using the NHS demographic service to deter-
mine whether patients had further NHS numbers or
known dates of death. Date of diagnosis was found to
be missing in 282 HCAI cases and updated where pos-
sible in March 2014 when further historical HCAI elec-
tronic pathology data became available. The dataset
was then reduced to patients resident in London who
had valid London postcodes. Those without valid post-
codes were assumed to be non-London residents or
other women who had attended from abroad, and were
excluded. Patients were then assigned to a socioeco-
nomic deprivation quintile based on their lower super
output area of residence (areas of around 1500 individ-
uals) using the income domain of the Indices of
deprivation 2007 [17].
Data on female residents of London diagnosed with
breast cancer during 2005 to 2011 were then extracted
from the former TCR dataset to provide a study compari-
son sample. Three patient groups were defined for ana-
lysis, 1) women receiving ‘only HCAI care’ (representing
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those found only within the HCAI provider data in the
study hospital, 2) women receiving ‘some HCAI care’
(representing those within both the HCAI provider and
the TCR datasets), and 3) Other London women known
only to TCR data (representing largely women receiving
NHS care, but also a small proportion cared for by other
London private providers). For those with information in
both datasets, where there were inconsistent values for
date of diagnosis, age, socioeconomic deprivation or stage,
registry data were given priority, and where these were ab-
sent or not known in the registry data the HCAI value
was included. Although we had information on whether
each woman had a record of receiving any surgery, radio-
therapy or chemotherapy, we did not have information on
whether this was missing rather than not recorded. There
was also insufficient detail available to reconstruct exactly
what each treatment had been, or where and when it had
been received.
This study was covered by section 251 of the Health
and Social Care Act which enables the collection and
analysis of data for cancer registration in the UK popula-
tion. This provision is not mandated in the UK and does
not currently apply directly to private hospital providers.
Unlike NHS trusts, private hospitals are required to ob-
tain explicit consent from patients for the transfer of
their data for cancer registration purposes. Following
legal advice a specific data agreement for the study was
established at the outset between HCAI (trading as The
Harley Street Clinic) and the former TCR to cover the
extraction, transfer, matching, tracing, and analysis of
data by registry staff in a similar way as for NHS data.
The cancer registration officer (EN) also signed a new
confidentiality agreement that allowed them to work
with new data systems in one HCAI office. The final
HCAI data were not processed onto the cancer registra-
tion system to undergo the usual quality assurance pro-
cedures that precede formal registration, but were
maintained instead securely as a separate dataset for the
study. The final analysis used anonymised data and eth-
ical approval was not required.
Data analysis
Patients who could not be verified as having a date of
diagnosis between 2005 and 2011 or living in London,
along with any registrations generated where the only in-
formation was from a death certificate were excluded.
The earliest tumour diagnosed was included and all sub-
sequent tumours excluded for patients who had multiple
tumours diagnosed in the period study.
Data on the three groups of ‘HCAI only’, ‘some HCAI’,
and TCR only women were compared in terms of pro-
portions by age, deprivation of area of residence, year of
diagnosis, stage of disease, ethnicity, screen-detection,
recorded treatment and receptor status. We calculated
and compared the overall survival of the three cohorts
of patients from date of pathological diagnosis to date of
death, or end of follow-up, determined as the end of
December 2012. Overall survival curves were estimated
using the Kaplan-Meier method and differences assessed
using a log-rank test. Cox regression analyses were used
to adjust sequentially for other variables after examining
data completeness. The variables included were age, so-
cioeconomic deprivation, year of diagnosis, stage of dis-
ease, and recorded treatment (any radiotherapy, surgery,
chemotherapy or hormonal therapy), with tests for het-
erogeneity or trend excluding not known categories used
where appropriate for each variable.
Results
Figure 1 shows the data flow for the HCAI and TCR re-
cords and the removal of data for women not diagnosed
in the study period, not resident in London, or with du-
plicate data or with registrations from a death certificate
only. The final study sample therefore included 199
women known only to HCAI data, 278 known to both
HCAI and TCR data, and 31,234 known only to TCR
data.
Table 1 shows the demographic and clinical character-
istics of these three study groups - 1) women receiving
‘HCAI care only’ 2) Women receiving ‘some HCAI care’
and 3) Other London women. The ‘HCAI care only’
group included a higher proportion of women aged
under 50 than the other London women (49.2 % vs
24.9 %), and a lower proportion aged over 70 (12.5 % vs
28.8 %). The mean ages were 53 and 54 in the ‘HCAI
care only’ and ‘some HCAI care’ groups, and 61 for other
London women. The ‘HCAI care only’, and ‘some HCAI
care’ groups also included a higher proportion of women
living within areas in the two more affluent quintiles
(47.8 % and 53.2 %, respectively) compared with 27.6 %
in the other London women group.
Overall the proportion of women for whom stage of
disease data was not known was higher in the ‘HCAI
care only’ group (45.2 %) than in either the other
London women (17.5 %) or the ‘some HCAI care’ group
(14.4 %). However, the not known proportion decreased
in the ‘HCAI care only’ group during the study period
from 48.7 % in 2005 to 27.3 % for those diagnosed in
2011. Early stage disease (stage 1 and 2) was less fre-
quent in women within the ‘HCAI care only’ group
(53.3 %) than in either the other London women
group (64.5 %) or the ‘some HCAI care’ group
(73.4 %). However, when only patients with a known
stage were included, 78 % of the other London women
group had early stage disease, compared with 86 % of
the ‘some HCAI care’ group and 97 % of the ‘HCAI
care only’ group.
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The proportion of women with screen-detected dis-
ease recorded within either the ‘HCAI care only’ (2.5 %)
or ‘some HCAI care’ (5.8 %) groups was much lower
than in the other London women group (25.0 %) The
‘some HCAI care’ group was more similar to the ‘HCAI
care only’ group than to the other London women group
for most characteristics except recorded treatment. Here
higher proportions of the ‘some HCAI care’ group had
surgery, radiotherapy, chemotherapy and hormone ther-
apy recorded compared with the other two groups. Eth-
nicity was much less well-recorded in the HCAI data
with 70.2 % (726/1033) of cases having incomplete data,
while hormone receptor status was poorly recorded in
each of the HCAI and the registration datasets for this
period. These two variables could therefore not be con-
sidered further in the analysis.
Figure 2 shows the Kaplan-Meier overall survival
curves for the three groups of women. The ‘HCAI care
only’ patients had a better overall survival than the other
London women, while the ‘some HCAI care’ patients
had a better survival still (log-rank p < 0.0001). Table 2
shows the Cox proportional regression analysis results.
The unadjusted hazard ratio (relative risk of mortality)
for ‘HCAI care only’ patients compared with other
London women was 0.48 (95 % confidence interval (CI):
0.32-0.74). After adjustment for age this survival advan-
tage attenuated substantially to 0.66 (95 % CI 0.43-1.02)
and was no longer statistically significant at the 5 %
level, and after adjustment for deprivation was 0.70
(95 % CI 0.46-1.08). Year of diagnosis made little differ-
ence, while further adjustment for stage of disease in-
creased the risk to 0.72 (95 % CI 0.47-1.10), and
Fig. 1 Data flow diagram for HCAI and cancer registration records included in the study
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treatment increased it further to 0.79 (95 % CI 0.51-
1.21). These results indicate that the main identified
driver of the lower risk of mortality in the ‘HCAI
care only’ women was age, with deprivation and treat-
ment having influential though lesser effects. The un-
adjusted hazard ratio for the ‘some HCAI care’
patients was 0.24 (95 % CI 0.14-0.41) and was in-
creased in a similar way to 0.48 (95 % CI 0.28-0.80)
in the fully adjusted model. Age and treatment were
the most influential drivers of lower risk of mortality
among this group. Deprivation had a similar effect as
in the ‘HCAI care only’ group.
Table 1 Demographic and clinical characteristics of women diagnosed with breast cancer 2005 to 2011 and receiving HCAI only
care or some HCAI care compared with other London women
HCAI care only Some HCAI care Other London women
N % N % N %
Number of cases 199 278 31,234
Mean age (years) 53 54 61
Age group
<50 98 49.2 131 47.1 7,792 24.9
50-59 33 16.6 56 20.1 7,243 23.2
60-69 43 21.6 58 20.9 7,210 23.1
70-79 17 8.5 18 6.5 4,783 15.3
80+ 8 4.0 15 5.4 4,206 13.5
Socioeconomic deprivation quintile
1 = Affluent 62 31.2 97 34.9 4,182 13.4
2 33 16.6 51 18.3 4,437 14.2
3 45 22.6 54 19.4 5,928 19.0
4 33 16.6 46 16.5 7,932 25.4
5 = Deprived 26 13.1 30 10.8 8,755 28.0
Year of diagnosis
2005 17 8.5 22 7.9 4,286 13.7
2006 19 9.5 32 11.5 4,153 13.3
2007 51 25.6 37 13.3 4,366 14.0
2008 30 15.1 38 13.7 4,400 14.1
2009 29 14.6 57 20.5 4,649 14.9
2010 42 21.1 59 21.2 4,723 15.1
2011 11 5.5 33 11.9 4,657 14.9
Stage of disease
1 64 32.2 109 39.2 9,836 31.5
2 42 21.1 95 34.2 10,311 33.0
3 1 0.5 28 10.1 2,979 9.5
4 2 1.0 6 2.2 2,639 8.4
Not known 90 45.2 40 14.4 5,469 17.5
Screening category
Not Screen-detected 194 97.5 262 94.2 23,430 75.0
Screen-detected 5 2.5 16 5.8 7,804 25.0
Treatment
Any cancer surgery 137 68.8 241 86.7 20,747 66.4
Any chemotherapy 61 30.7 140 50.4 9,841 31.5
Any radiotherapy 78 39.2 140 50.4 8,197 26.2
Any hormone therapy 40 20.1 121 43.5 8,964 28.7
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Discussion
Summary of main findings
This study tested for the first time the retrospective ex-
change and transfer of breast cancer data for 2005 to
2011 between one private cancer care provider and the
cancer registration service for London. While the ex-
change exercise was possible, the sample size was rela-
tively small and we found that lack of comparable data
for some key variables in the private provider data lim-
ited the conclusions we could draw from the analyses.
We found that women receiving all or some of their care
within one HCAI provider were often younger, living
within areas of higher affluence, and less likely to be re-
corded as having screen-detected disease than other
London women. However, disease stage, which is a key
prognostic variable was less completely recorded within
HCAI data than in cancer registration data, and HCAI
women less often had early stage disease recorded than
other London women. Using the available data on stage
we found that women within the HCAI data appeared to
have a better survival from their breast cancer than
other London women, which was partly explained by
their differing age, deprivation and recorded treatment.
Data on ethnicity, tumour receptor status, and some as-
pects of specific treatment pathways were not available
and could not be considered as explanatory variables.
Limitations of the study
This is the first time that a large scale retrospective data
exchange and transfer has been attempted between a
private cancer provider and the cancer registration ser-
vice for London where a significant proportion of private
providers operate. As expected this was a complex
undertaking and we found some problems emerging
which limited the comparison of case mix and outcome
that we could make. These included a wide catchment
area for HCAI patients that substantially reduced the
study sample of London residents, and differences in
data collection and recording between the two systems
despite similar data extraction techniques being used to
create the new dataset.
To our knowledge there are no other published studies
of case mix or outcomes for private cancer providers in
the UK with which to compare our provisional findings.
A significant difficulty for this study was the differential
lack of high quality historical private sector data for key
variables of a comparable quality to NHS data. Data on
disease stage data were incomplete, though improving
within the HCAI records and this limited the adequacy
of the comparison and case mix adjustment that we
could undertake in this analysis. It is possible, for ex-
ample, that the lower proportion of early stage disease in
the ‘HCAI only’ women was simply an artefact of the
less complete recording of stage within HCAI data. To
assess this possibility we undertook a series of sensitivity
analyses. We carried out a complete case analysis and
also used multiple imputation (20 imputations based on
care group, age, deprivation, year of diagnosis, whether
the cancer was screen-detected, treatment received,
length of survival, and whether the patient was alive at
the end of the study period). The complete case analysis
increased the hazard ratios (fully adjusted ‘HCAI care
only’: 1.28, 95 % CI: 0.71-2.32, ‘some HCAI care’: 0.63,
95 % CI 0.35-1.11, so that there was no statistically sig-
nificant difference in the survival of all three groups.
Multiple imputation gave a similar stage distribution in
the two HCAI care groups (‘HCAI care only’: 44 % stage
1, 40 % stage 2, 10 % stage 3, 7 % stage 4; ‘some HCAI
Fig. 2 Kaplan-Meier survival estimates for women with breast cancer receiving HCAI only care, some HCAI care compared with other
London women
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Table 2 Mortality hazard ratios for women diagnosed with breast cancer between 2005 and 2011 and receiving HCAI care only and some HCAI care compared with other
London women
Unadjusted Adjusted for age Adjusted for age and
deprivation
Adjusted for age, deprivation,
and year of diagnosis
Adjusted for age, deprivation,
year of diagnosis, and stage
Adjusted for age, deprivation,
year of diagnosis, stage, and
treatment
HR (95 % CI) HR (95 % CI) HR (95 % CI) HR (95 % CI) HR (95 % CI) HR (95 % CI)
Other London women 1.00 1.00 1.00 1.00 1.00 1.00
HCAI care only 0.48 (0.32, 0.74) 0.66 (0.43, 1.02) 0.70 (0.46, 1.08) 0.70 (0.45, 1.07) 0.72 (0.47, 1.10) 0.79 (0.51, 1.21)
Some HCAI care 0.24 (0.14, 0.41) 0.32 (0.19, 0.54) 0.34 (0.20, 0.58) 0.35 (0.21, 0.59) 0.40 (0.24, 0.67) 0.48 (0.28, 0.80)
χ2-test (2 d.f.) 39.35 21.69 18.40 18.30 14.03 8.83
p-heterogeneity <0.0001 <0.0001 <0.0001 0.0001 0.0009 0.0121
Age group
<40 1.00 1.00 1.00 1.00 1.00
40-44 0.85 (0.72, 1.01) 0.86 (0.73, 1.02) 0.86 (0.73, 1.02) 0.88 (0.74, 1.03) 0.96 (0.81, 1.13)
45-49 0.77 (0.65, 0.89) 0.78 (0.67, 0.91) 0.78 (0.67, 0.92) 0.81 (0.70, 0.95) 0.89 (0.76, 1.04)
50-54 0.65 (0.56, 0.77) 0.67 (0.57, 0.78) 0.67 (0.57, 0.78) 0.78 (0.66, 0.91) 0.86 (0.74, 1.01)
55-59 0.83 (0.72, 0.97) 0.86 (0.74, 1.00) 0.85 (0.74, 0.99) 0.97 (0.84, 1.13) 1.11 (0.95, 1.29)
60-64 0.85 (0.73, 0.99) 0.88 (0.76, 1.02) 0.88 (0.76, 1.02) 1.06 (0.91, 1.23) 1.27 (1.10, 1.48)
65-69 1.05 (0.91, 1.21) 1.08 (0.93, 1.25) 1.08 (0.93, 1.24) 1.30 (1.12, 1.50) 1.65 (1.42, 1.91)
70-74 2.01 (1.74, 2.30) 2.07 (1.80, 2.39) 2.07 (1.80, 2.38) 2.24 (1.95, 2.58) 2.83 (2.45, 3.27)
75-79 2.85 (2.49, 3.26) 2.94 (2.57, 3.36) 2.94 (2.57, 3.36) 3.08 (2.69, 3.53) 3.91 (3.40, 4.50)
80+ 6.19 (5.48, 6.99) 6.41 (5.67, 7.24) 6.42 (5.69, 7.26) 6.10 (5.40, 6.89) 6.87 (6.03, 7.82)
χ2-test (1 d.f.) 2,755.90 2,804.15 2,804.01 2,540.64 2,052.19
p-trend <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
Socioeconomic deprivation quintile
1 = Affluent 1.00 1.00 1.00 1.00
2 0.97 (0.88, 1.07) 0.96 (0.87, 1.06) 0.97 (0.87, 1.07) 0.97 (0.87, 1.07)
3 1.06 (0.96, 1.16) 1.05 (0.96, 1.15) 1.04 (0.95, 1.15) 1.04 (0.95, 1.14)
4 1.18 (1.08, 1.29) 1.18 (1.08, 1.29) 1.19 (1.09, 1.30) 1.16 (1.07, 1.27)
5 = Deprived 1.37 (1.26, 1.49) 1.36 (1.25, 1.48) 1.27 (1.17, 1.38) 1.22 (1.12, 1.33)
χ2-test (1 d.f.) 92.81 92.14 61.05 44.50
p-trend <0.0001 <0.0001 <0.0001 <0.0001
D
avies
et
al.BM
C
Cancer
 (2016) 16:421 
Page
8
of
13
Table 2 Mortality hazard ratios for women diagnosed with breast cancer between 2005 and 2011 and receiving HCAI care only and some HCAI care compared with other
London women (Continued)
Year of diagnosis
2005 1.00 1.00 1.00
2006 0.99 (0.91, 1.07) 1.08 (0.99, 1.17) 1.08 (1.00, 1.17)
2007 1.00 (0.92, 1.09) 1.10 (1.02, 1.20) 1.07 (0.98, 1.16)
2008 0.98 (0.89, 1.06) 1.11 (1.01, 1.21) 1.02 (0.93, 1.11)
2009 0.87 (0.79, 0.96) 0.93 (0.85, 1.03) 0.87 (0.80, 0.96)
2010 0.81 (0.73, 0.90) 0.82 (0.74, 0.91) 0.84 (0.76, 0.93)
2011 0.74 (0.65, 0.84) 0.81 (0.72, 0.92) 0.83 (0.73, 0.94)
χ2-test (1 d.f.) 33.22 22.52 27.02
p-trend <0.0001 <0.0001 <0.0001
Stage of disease
1 1.00 1.00
2 1.02 (0.94, 1.11) 1.10 (1.01, 1.19)
3 2.28 (2.07, 2.51) 2.27 (2.06, 2.51)
4 6.37 (5.89, 6.90) 4.90 (4.52, 5.31)
Not known 2.67 (2.47, 2.88) 1.82 (1.68, 1.96)
χ2-test (1 d.f.) 2,924.02 1,630.20
Excl. NK p-trend <0.0001 <0.0001
Radiotherapy
No 1.00
Yes 0.82 (0.77, 0.89)
χ2-test (1 d.f.) 28.19
p-heterogeneity <0.0001
Chemotherapy
No 1.00
Yes 1.29 (1.20, 1.38)
χ2-test (1 d.f.) 50.87
p-heterogeneity <0.0001
Cancer surgery
No 1.00
Yes 0.40 (0.37, 0.42)
D
avies
et
al.BM
C
Cancer
 (2016) 16:421 
Page
9
of
13
Table 2 Mortality hazard ratios for women diagnosed with breast cancer between 2005 and 2011 and receiving HCAI care only and some HCAI care compared with other
London women (Continued)
χ2-test (1 d.f.) 962.80
p-heterogeneity <0.0001
Hormone therapy
No 1.00
Yes 0.80 (0.75, 0.85)
χ2-test (1 d.f.) 58.07
p-heterogeneity <0.0001
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care’: 45 % stage 1, 39 % stage 2, 9 % stage 3, 7 % stage
4). There were 32 % of other London women imputed as
having stage 1 disease, 41 % with stage 2, 14 % with
stage 3, and 13 % with stage 4. The fully adjusted results
using these imputed stage values were similar to the ori-
ginal results, particularly for the ‘some HCAI care’ group
(0.40, 95 % CI: 0.29-0.68), though attenuated for the
‘HCAI care only’ group (0.89, 95 % CI: 0.57-1.38).
We also calculated 5-year net survival for the three
groups, which takes background mortality into account,
but not the differences in case mix and other factors be-
tween the groups. This was lowest for the other London
women (84.1 %, 95 % CI: 83.4 %-84.8 %), higher for the
‘HCAI care only’ (93.6 %, 95 % CI: 86.8 %-97.0 %) and
highest in the ‘some HCAI care’ group (97.3 %, 95 % CI:
86.7 %-99.5 %).
We also did not have complete data on other tumour
factors or detailed information on treatment pathways
that could have influenced outcome. It would have been
preferable to have been able to subject these data to the
same quality assurance and querying processes from the
outset including for pathological diagnosis as occurs for
data received for cancer registration from NHS hospitals
in England. Indeed the fact that cancer registration is
not mandated for cases diagnosed or treated in the pri-
vate sector in the UK, unlike the situation for other
countries means that this lever for quality improvement
of the data is not yet available. Overall it also seems
likely that some treatment data was missing in all three
study groups. We would expect these data to be improv-
ing in completeness in more recent years. Screening in-
formation may also have been incomplete for those
women who only received HCAI care and were diag-
nosed through the NHS screening programme. For this
reason we did not include the screen-detected variable
in the survival analyses. However, when we included the
screening information in the fully adjusted model the
conclusions remained the same, although the hazard ra-
tios decreased to 0.69 (95 % CI 0.45-1.07) for the ‘HCAI
care only’ group, and 0.43 (0.26-0.73) for the ‘some
HCAI care’ group.
Implications for policy and practice
We hope that this feasibility study will inform debate
about the evidence for the private sector providing ser-
vices to NHS patients by showing how cancer registra-
tion data could be collected from this sector and used to
provide new information for the NHS, private providers,
policy makers and the public. Collecting data from pri-
vate providers of cancer services is one goal of the Na-
tional Cancer Registration and Analysis Service within
PHE [18]. Although English public health datasets aim
to provide comprehensive coverage, in practice they ex-
clude a small proportion of the population who opt to
pay for private insurance, private healthcare services, or
have these provided for them by their employers. For ex-
ample, HES data, which are the main source of ethnicity
data for many analyses of English hospital care, do not
include data on all admissions to private hospitals.
Despite the long-standing interest of NHS and some
private providers in discussing more frequent data ex-
change to inform the monitoring of commissioning deci-
sions [19], there seem to have been barriers to overcome
in making these practices routine. The consequence is a
number of unanswered questions, particularly for cancer
patients in London, about the uptake of cancer screen-
ing, the presentation of disease in different population
groups and their outcomes. Some of these may be an-
swered as HCAI and other private providers improve
data collection within their systems towards NHS stan-
dards to allow further retrospective comparison. Other
initiatives by the Care Quality Commission are also
seeking to increase the information available about care
within the independent sector [20]. If contracts with pri-
vate providers are to become a part of the long-term
provision for the NHS, they will need to be monitored
and evaluated in a similar way to NHS services. One op-
tion to help improve cancer data quality in the private
health sector would be the make cancer registration rou-
tine or mandatory in the same way as in other countries.
While this would likely require political, business, legal
and public debate the benefits of full population cover-
age would be significant. The findings of our study fur-
ther suggest that comparing outcomes may be complex,
particularly where patients move between providers in
different sectors. In addition part of the better outcome
for private providers suggested here may be explained by
characteristics of women who select HCAI care or are
selected into this care by their insurance policies. This
would not be the situation for any future NHS service
contracts where a representative section of London
women might be expected to receive treatment in pri-
vate sector hospitals.
Implications for future research
Our study opens the way for larger comparative studies
of breast cancer and other cancers treated across all
HCAI providers in London, and by other private health
care providers across the UK. Particular questions to be
answered in addition to the issue of comparable stage
data include whether there are differences in the ethni-
city or tumour receptor status of patients receiving treat-
ment by HCAI, whether delays in diagnosis, the
treatments patients receive or the time they wait for
them differs, and how women currently move between
private and NHS care. The finding that women receiving
'some HCAI care' appeared to have better outcomes
than the other two groups is intriguing but could clearly
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be a singular finding and requires replication in further
larger datasets. One hypothesis is that it represents other
unmeasured behavioural factors including women’s abil-
ity to negotiate two health sectors and receive several
opinions on their treatment. For example, women with
private insurance who have breast cancer detected at
NHS screening could opt for initial private surgery and
return to the NHS for later treatment when their insur-
ance funds are depleted. In this respect the low rate of
screen-detected disease in women receiving HCAI care
was surprising given that our previous study of London
NHS screening data had led us to suggest that women in
the most affluent group may have been more likely to be
diagnosed privately because they had lower screening up-
take in some areas of London [17]. The findings in this
new study could be a feature of the women attending this
particular HCAI hospital or reflect the fact that this infor-
mation is not recorded within HCAI data because insur-
ance companies do not often support screening. Another
unexpected finding was that patients who received HCAI
and other care had more complete data for both stage of
disease and treatment. This could be a consequence of
better recording of data within the NHS, or could repre-
sent another singular finding from this relatively small
study in one geographical area. A complete population-
based view of London women being diagnosed and receiv-
ing treatment for breast cancer from all providers would
therefore produce a more accurate picture of inequalities
in outcome between different socioeconomic groups. We
would hope that this will show where data is still needed
to make a judgement about the size of and contributors to
these inequalities, and possibly indicate new opportunities
for reducing them.
Conclusions
Exchange of data between the private cancer sector
and the English cancer registration service can iden-
tify patients who receive all or some private care. The
better survival of women receiving only or some
HCAI breast cancer care appears to be at least partly
explained by demographic, disease, and treatment fac-
tors. However, larger studies using similarly quality
assured datasets and more complete staging data from
the private sector are needed to produce definitive
comparative results.
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